Goal Reached Thanks to every supporter — we hit 100%!

Goal: 1000 CNY · Raised: 1336 CNY

100%

CVE-2021-41835— Fresenius Kabi Agilia Connect Infusion System use of a broken or risky cryptographic algorithm

Quick assessment

Affected
Fresenius Kabi Agilia Link+
Exploitation
No confirmed in-the-wild exploitation; assess based on exposure
Recommended action
Check the vendor advisory and references for a fixed version. If immediate upgrade is impossible, restrict exposure and increase monitoring.

Fresenius Kabi Agilia Connect Infusion System是德国Fresenius Kabi公司的一个输液系统。 Fresenius Kabi Agilia Connect Infusion System 中存在加密问题漏洞,该漏洞源于产品使用明文传输数据。攻击者可通过该漏洞获得敏感信息。

CVSS 7.3 · High EPSS 0.30% · P23

Possible ATT&CK Techniques 2 AI

T1557 · Adversary-in-the-Middle T1043
Get alerts for future matching vulnerabilities Log in to subscribe

I. Basic Information for CVE-2021-41835

Vulnerability Information

Have questions about the vulnerability? See if Shenlong's analysis helps!
View Shenlong Deep Dive ↗

Although we use advanced large model technology, its output may still contain inaccurate or outdated information.Shenlong tries to ensure data accuracy, but please verify and judge based on the actual situation.

Vulnerability Title
Fresenius Kabi Agilia Connect Infusion System use of a broken or risky cryptographic algorithm
Source: CVE Program / CVE List V5
Vulnerability Description
Fresenius Kabi Agilia Link + version 3.0 does not enforce transport layer encryption. Therefore, transmitted data may be sent in cleartext. Transport layer encryption is offered on Port TCP/443, but the affected service does not perform an automated redirect from the unencrypted service on Port TCP/80 to the encrypted service.
Source: CVE Program / CVE List V5
CVSS Information
CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:L/I:L/A:L
Source: CVE Program / CVE List V5
Vulnerability Type
使用已被攻破或存在风险的密码学算法
Source: CVE Program / CVE List V5
Vulnerability Title
Fresenius Kabi Agilia Connect Infusion System 加密问题漏洞
Source: CNNVD (China National Vulnerability Database)
Vulnerability Description
Fresenius Kabi Agilia Connect Infusion System是德国Fresenius Kabi公司的一个输液系统。 Fresenius Kabi Agilia Connect Infusion System 中存在加密问题漏洞,该漏洞源于产品使用明文传输数据。攻击者可通过该漏洞获得敏感信息。
Source: CNNVD (China National Vulnerability Database)
CVSS Information
N/A
Source: CNNVD (China National Vulnerability Database)
Vulnerability Type
N/A
Source: CNNVD (China National Vulnerability Database)

Affected Products

Vendor Product Affected Versions CPE Subscribe
Fresenius Kabi Agilia Link+ unspecified ~ 3.0 -

II. Public POCs for CVE-2021-41835

# POC Description Source Link Shenlong Link
AI-Generated POC Premium

No public POC found.

Login to generate AI POC

III. Intelligence Information for CVE-2021-41835

登录查看更多情报信息。

Vendor Advisories for CVE-2021-41835 (1)

Same Patch Batch · Fresenius Kabi · 2022-01-21 · 12 CVEs total

CVE-2021-23236 7.5 HIGH Fresenius Kabi Agilia Connect Infusion System uncontrolled resource consumption
CVE-2021-23196 7.3 HIGH Fresenius Kabi Agilia Connect Infusion System insufficiently protected credentials
CVE-2021-23233 7.3 HIGH Fresenius Kabi Agilia Connect Infusion System
CVE-2021-43355 7.3 HIGH Fresenius Kabi Agilia Connect Infusion System use of client side authentication
CVE-2021-23207 6.5 MEDIUM Fresenius Kabi Agilia Connect Infusion System plaintext storage of a password
CVE-2021-31562 6.5 MEDIUM Fresenius Kabi Agilia Connect Infusion System use of a broken or risky cryptographic algor
CVE-2021-44464 6.3 MEDIUM Fresenius Kabi Agilia Connect Infusion System hard coded credentials
CVE-2021-33846 5.9 MEDIUM Fresenius Kabi Agilia Connect Infusion System use of a broken or risky cryptographic algor
CVE-2021-33848 5.4 MEDIUM Fresenius Kabi Agilia Connect Infusion System cross site scripting
CVE-2021-23195 5.3 MEDIUM Fresenius Kabi Agilia Connect Infusion System exposure of information through directory li
CVE-2021-33843 5.3 MEDIUM Fresenius Kabi Agilia Connect Infusion System files or directories accessible to external

IV. Related Vulnerabilities

V. Comments for CVE-2021-41835

No comments yet


Leave a comment